These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2878941)

  • 21. [Treatment of acute phase of myocardial infarction with injectable bisoprolol with oral versus].
    Grollier G; Samoyeau R; Potier JC
    Therapie; 1991; 46(2):147-54. PubMed ID: 1675817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single oral dose pharmacokinetics of bisoprolol 10 mg in liver disease.
    Hayes PC; Jenkins D; Vavianos P; Dagap K; Johnston A; Ioannides C; Thomas P; Williams R
    Eur Heart J; 1987 Dec; 8 Suppl M():23-9. PubMed ID: 2897298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of the new beta-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administration.
    Bianchetti G; Blatrix C; Gomeni R; Kilborn JR; Larribaud J; Lücker PW; Thebault JJ; Trocherie S; Morselli PL
    Arzneimittelforschung; 1980; 30(11):1912-6. PubMed ID: 6109538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisoprolol (EMD 33512), a highly selective beta 1-adrenoceptor antagonist: in vitro and in vivo studies.
    Brodde OE
    J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S29-35. PubMed ID: 2439795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies.
    Bundkirchen A; Brixius K; Bölck B; Nguyen Q; Schwinger RH
    Eur J Pharmacol; 2003 Jan; 460(1):19-26. PubMed ID: 12535855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist.
    Leopold G; Ungethüm W; Pabst J; Simane Z; Bühring KU; Wiemann H
    Br J Clin Pharmacol; 1986 Sep; 22(3):293-300. PubMed ID: 2876722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat.
    Lennernäs H; Regårdh CG
    Pharm Res; 1993 May; 10(5):727-31. PubMed ID: 8100631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of flestolol in man: preliminary data.
    Achari R; Hulse JD; Drissel D; Matier WL
    Br J Clin Pharmacol; 1985 Dec; 20(6):691-4. PubMed ID: 2868745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and metabolism of a new beta-adrenergic blocking agent, the 1, ter-butyl-amino-3-(1,2,3,4-tetrahydro-1,4-ethano-8-hydroxy-5-naphthoxy)-2-propanol (K 5407).
    Goldaniga G; Montesanti L; Pianezzola E; Valzelli G
    Eur J Drug Metab Pharmacokinet; 1980; 5(1):9-20. PubMed ID: 6104601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and disposition of carvedilol in humans.
    Neugebauer G; Akpan W; von Möllendorff E; Neubert P; Reiff K
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S85-8. PubMed ID: 2454375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the pharmacokinetics of talinolol, a new beta 1-receptor blocking agent.
    Haustein KO; Fritzsche K
    Int J Clin Pharmacol Ther Toxicol; 1981 Sep; 19(9):392-5. PubMed ID: 6117520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of single and multiple doses of flusoxolol (Ro 31-1411) in healthy subjects.
    Gillies HC; Rogers HJ; Francis RJ; Galloway DB; Humphreys JE
    Eur J Clin Pharmacol; 1986; 31(1):113-5. PubMed ID: 2877883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and ADME Characterization of Intravenous and Oral [
    Zamek-Gliszczynski MJ; Kenworthy D; Bershas DA; Sanghvi M; Pereira AI; Mudunuru J; Crossman L; Pirhalla JL; Thorpe KM; Dennison JMTJ; McLaughlin MM; Allinder M; Swift B; O'Connor-Semmes RL; Young GC
    Drug Metab Dispos; 2021 Dec; 49(12):1109-1117. PubMed ID: 34625435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis.
    Regårdh CG; Jordö L; Ervik M; Lundborg P; Olsson R; Rönn O
    Clin Pharmacokinet; 1981; 6(5):375-88. PubMed ID: 7333059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of adimolol after single and multiple dose administration in healthy volunteers.
    Wiedemann I; Peil H; Justus H; Adamus S; Brantl V; Lohmann H
    Arzneimittelforschung; 1985; 35(6):964-9. PubMed ID: 2862877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers.
    Le Coz F; Sauleman P; Poirier JM; Cuche JL; Midavaine M; Rames A; Lecocq B; Jaillon P
    J Cardiovasc Pharmacol; 1991 Jul; 18(1):28-34. PubMed ID: 1719288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.
    O'Connor PC; Arnold JM; Brown AN; Francis RJ; Finch MB; Galloway DB; Harron DW; McDevitt DG; Shanks RG
    Br J Clin Pharmacol; 1985 Mar; 19(3):319-27. PubMed ID: 2859047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-adrenoceptor-binding studies of the cardioselective beta blockers bisoprolol, H-I 42 BS, and HX-CH 44 BS to heart membranes and intact ventricular myocytes of adult rats: two beta 1-binding sites for bisoprolol.
    Mauz AB; Pelzer H
    J Cardiovasc Pharmacol; 1990 Mar; 15(3):421-7. PubMed ID: 1691366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic fate of the beta-blocker 14C-bupranolol in humans, dogs, and rhesus monkeys.
    Waller AR; Chasseaud LF; Bonn R; Taylor T; Darragh A; Girkin R; Down WH; Doyle E
    Drug Metab Dispos; 1982; 10(1):51-4. PubMed ID: 6124383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.